Getinge (GETI.B) AI Stock Analysis

• Market Cap: kr58.12B
• Dividend Yield: 2.16%
• Average Volume (3M): 487.24K
• Price to Earnings (P/E): 38.6
• Beta (1Y): 0.88
• Revenue Growth: 6.51%
• EPS Growth: -42.34%
• Country: SE
• Employees: 11,827
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 2.25
• Shares Outstanding: 254,152,370
• 10 Day Avg. Volume: 574,772
• 30 Day Avg. Volume: 487,242
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: kr188.33
• Price Target Upside: -11.67% Downside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 3

• Rating: 62 Neutral
• Price Target: kr218.00 ▲(2.25% Upside)

Getinge's overall stock score is primarily influenced by its stable financial performance, despite challenges in revenue growth and ROE. The technical analysis suggests a neutral market sentiment, while the valuation indicates potential overvaluation concerns. The absence of earnings call and corporate events data limits additional insights.

Getinge Business Overview & Revenue Model

Company Description

Getinge AB (GETI.B) is a global medical technology company headquartered in Sweden, specializing in products and solutions for healthcare and life sciences. The company operates primarily in two sectors: Acute Care Therapies and Surgical Workflows. Getinge offers a diverse range of products including critical care equipment, surgical instruments, sterilization solutions, and hospital logistics systems, aimed at enhancing patient outcomes and optimizing healthcare processes.

How the Company Makes Money

Getinge generates revenue through the sale of medical devices, equipment, and related services within its core segments. The Acute Care Therapies division, which includes products such as ventilators, cardiopulmonary devices, and perfusion systems, represents a significant revenue stream, particularly in critical care settings. The Surgical Workflows segment contributes through the sale of surgical instruments, operating room equipment, and sterilization systems. Additionally, the company benefits from recurring revenue through service contracts, maintenance, and parts supply for its devices. Strategic partnerships and collaborations with hospitals, healthcare providers, and research institutions also enhance its market presence and drive sales, particularly in emerging markets where healthcare infrastructure is expanding.

Getinge Financial Statement Overview

Summary

Getinge demonstrates a stable financial position with consistent profitability margins and improving cash flow generation. However, the significant decline in revenue growth and lower ROE are areas that require attention. The company maintains a moderate leverage position, which supports its financial stability.

Income Statement

Getinge's income statement shows a mixed performance. The TTM data indicates a decline in revenue growth rate by 18.8%, which is concerning. However, the company maintains a stable gross profit margin of approximately 46.9% and a net profit margin of 4.2%. The EBIT and EBITDA margins are also reasonable at 10.8% and 17.9%, respectively. Despite the revenue decline, the company has managed to sustain its profitability margins, which is a positive sign.

Balance Sheet

The balance sheet reflects a stable financial position with a debt-to-equity ratio of 0.39, indicating moderate leverage. The return on equity (ROE) is 4.9%, which is lower than previous years, suggesting a decrease in profitability relative to equity. The equity ratio stands at 51.1%, showing a solid equity base. Overall, the balance sheet is stable, but the declining ROE is a point of concern.

Cash Flow

Cash flow analysis reveals a positive free cash flow growth rate of 8.9% in the TTM period, indicating improved cash generation. The operating cash flow to net income ratio is 0.31, and the free cash flow to net income ratio is 0.67, both showing adequate cash flow coverage. While cash flow generation is improving, the ratios suggest room for enhancing cash efficiency.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	35.50B	34.76B	31.83B	28.29B	27.05B	29.82B
Gross Profit	16.64B	16.15B	14.49B	13.41B	13.58B	14.72B
EBITDA	6.37B	5.31B	5.93B	5.73B	6.20B	6.46B
Net Income	1.49B	1.64B	2.41B	2.49B	2.97B	3.24B
Balance Sheet
Total Assets	56.37B	63.92B	53.59B	52.03B	44.55B	45.01B
Cash, Cash Equivalents and Short-Term Investments	1.95B	2.96B	2.73B	5.68B	4.08B	6.06B
Total Debt	11.17B	10.73B	8.08B	5.82B	4.31B	10.21B
Total Liabilities	27.35B	30.71B	23.18B	21.58B	19.38B	23.53B
Stockholders Equity	28.82B	33.01B	30.17B	30.04B	24.75B	21.02B
Cash Flow
Free Cash Flow	2.70B	3.27B	1.60B	2.23B	5.63B	6.15B
Operating Cash Flow	4.03B	4.58B	2.96B	3.37B	6.56B	7.20B
Investing Cash Flow	-5.85B	-4.55B	-6.54B	-1.47B	-1.33B	-1.99B
Financing Cash Flow	1.50B	504.00M	511.00M	-500.00M	-7.24B	-297.00M

Getinge Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 213.20
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:GETI.B, the sentiment is Positive. The current price of 213.2 is above the 20-day moving average (MA) of 209.28, above the 50-day MA of 205.38, and above the 200-day MA of 197.39, indicating a bullish trend. The MACD of 0.98 indicates Negative momentum. The RSI at 59.80 is Neutral, neither overbought nor oversold. The STOCH value of 86.78 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:GETI.B.

Getinge Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CEVI	71 Outperform	$4.39B	28.15	18.65%	1.37%	3.45%	4.22%
GETI.B	62 Neutral	kr58.12B	38.63	4.94%	2.16%	6.51%	-42.34%
SECT.B	59 Neutral	€59.55B	99.60	31.78%	0.36%	5.74%	30.96%
VITR	57 Neutral	kr19.19B	42.17	3.46%	0.79%	0.14%	―
XVIVO	57 Neutral	$5.52B	49.55	5.17%	―	17.78%	-7.83%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SEDANA	48 Neutral	€1.24B	―	-5.40%	―	16.27%	-22.61%

Getinge Corporate Events

Getinge’s Cardiosave Intra-Aortic Balloon Pump CE Mark Reinstated

Getinge has announced that the EU CE Mark for its Cardiosave Intra-Aortic Balloon Pump has been reinstated by the EU Notified Body TÜV SÜD after addressing compliance gaps and implementing design improvements. This reinstatement allows Getinge to resume deliveries of the device to markets accepting the CE mark, ensuring healthcare professionals and patients have access to this critical cardiac care device.

The most recent analyst rating on ($SE:GETI.B) stock is a Sell with a SEK180.00 price target. To see the full list of analyst forecasts on Getinge stock, see the SE:GETI.B Stock Forecast page.

Getinge Announces Q2 2025 Report and Conference Call

Getinge has announced its Q2 Report 2025 will be released on July 18, 2025, followed by a conference call hosted by the company’s President & CEO and CFO. This event invites fund managers, analysts, and media to participate, potentially impacting stakeholders by providing insights into the company’s financial performance and strategic direction.

The most recent analyst rating on ($SE:GETI.B) stock is a Sell with a SEK190.00 price target. To see the full list of analyst forecasts on Getinge stock, see the SE:GETI.B Stock Forecast page.